1

# Title: Impact of Cardiac Position, Morphology and Operative Technique on Long Term Fontan Outcomes in Heterotaxy

4

Author: Sachiko Kadowaki, MD, PhD<sup>1,2</sup>; Zeynep uçar MD, PhD<sup>1,3</sup>; Chun-Po Steve Fan,
PhD, P.Stat<sup>4</sup>; Yasmin Zahiri BSc<sup>1,2</sup>; Kok Hooi Yap, MD, MSc<sup>1,2</sup>; Teerapong
Tocharoenchok, MD, PhD<sup>1,2</sup>; Weidan Chen, MD, PhD<sup>1,5</sup>; Anne I. Dipchand, MD, FRCPC<sup>6</sup>;
Osami Honjo, MD, PhD<sup>1,2</sup>; David J. Barron, MD, PhD<sup>1,2</sup>

9

Affiliation: 1 Division of Cardiovascular Surgery, The Labatt Family Heart Centre, The 10 Hospital for Sick Children, Toronto, ON, Canada; 2 Department of Surgery, University of 11 Toronto, ON, Canada; 3 Division of Cardiovascular Surgery, Koc University, GSSE, 12 13 Istanbul; 4 Ted Rogers Centre for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada; 5 Department of Cardiac Surgery, Guangzhou 14 Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 15 China; 6 Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada 16 17**Short title:** Fontan long-term outcome in heterotaxy Corresponding author: David J. Barron, M.D., Ph.D., Division of Cardiovascular 18 19 Surgery, Labatt Family Heart Centre, The Hospital for Sick Children, SickKids Patient

20 Support Centre, 175 Elizabeth St, Toronto, Ontario, Canada. M5G 2G3. E-mail:

- 21 david.barron@sickkids.ca
- 22 Word count: 5486 words
- 23 This submission is for annual Cardiovascular Surgery-Themed Issue.

#### 24 Abstract

25 **Objectives:** Heterotaxy is characterized by complex venous connections and cardiac 26 position requiring individualized strategies for Fontan. This study aimed to assess 25-year 27 outcomes of heterotaxy patients undergone Fontan operation, with particular focus on 28 morphological features and surgical techniques.

Methods: 82 consecutive heterotaxy patients who underwent Fontan operation from 1985 to 2021 were compared to 150 with tricuspid atresia (TA) and 144 with hypoplastic left heart syndrome (HLHS). Kaplan-Meier method and Cox proportional hazard model were used for transplant-free survival and predictor analysis.

**Results:** Right Atrial Isomerism (RAI) was present in 45 cases and Left Atrial Isomerism 33 34 (LAI) in 37. The 20-year transplant-free survival was comparable between the groups (RAI vs. LAI, 76% [95% confidence interval, 57-87%] vs. 68% [47-82%], p=0.22). 35 Techniques were extracardiac in 66%, intra-atrial conduit in 9%, lateral tunnel in 18%. 36 More intervention on pulmonary veins occurred in the RAI group. Cardiac position and 37 38 apicocaval juxtaposition did not influence outcome. The IVC-contralateral PA Fontan was 39 associated with 100% survival, while the IVC-ipsilateral PA Fontan at the side of the 40 cardiac apex showed 67% [34-87%] survival at 20 years. Moderate or severe ventricular dysfunction at 20 years was found in 15% (6-39%) and 0% of RAI and LAI patients among 41 42 hospital survivors, respectively (p=0.09). In-hospital mortality was higher in heterotaxy 43 (9.8% [5-19%]) compared to TA (1.3% [0.3-5.3%], p<.01) and HLHS (2.8% [1.1-7.3%], p=0.02). There was no in-hospital death after 2000 in any of groups. The 20-year 44 45 transplant-free survival in heterotaxy (72% [59-82%]) was worse than that in TA (95% [89-46 97%], p<0.001) but was not significantly different from that in HLHS (80% [69-87%],

47 p=0.11). Reintervention rate at 20 years was significantly higher in heterotaxy (18% [11-29%]) vs. HLHS (8% [4-16%]) (p=0.01). Ventricular dysfunction was a predictor for death 48 (univariate p<0.001). 49 50 **Conclusion:** Various routing techniques can be successfully applied to overcome the anatomical challenges of heterotaxy. Although higher in-hospital mortality and 51 52 reintervention rate were found in heterotaxy in the early era, overall survival post Fontan was similar to that in HLHS. RAI had comparable survival to LAI with greater proportion 53 requiring pulmonary vein intervention at time of Fontan. 54 55

- 56
- 57

### 58 Introduction

59 Heterotaxy is a challenging surgical subtype in congenital heart disease, characterized by abnormal systemic and pulmonary venous (PV) connections, unusual cardiac position, 60 such as apicocaval juxtaposition (ACJ), and high incidence of common atrioventricular 61 (AV) valve [1]. More than 75% of heterotaxy cases have a functional single ventricle, and 62 63 so are destined for staged single ventricle palliation and subsequent Fontan operation [2,3]. The associated extracardiac anomalies add further challenges to the already 64 65 suboptimal single ventricle circulation, including hepatic disease and ciliary dyskinesia [4,5]. Consequently, Fontan palliation in heterotaxy, right atrial isomerism (RAI) in 66 particular, is renowned for higher mortality and morbidity [6-12]. 67

68

69 Reports of Fontan outcomes in heterotaxy have been hampered by small case numbers, selection biases, variations in follow-up duration, and a lack of comparable non 70 71 heterotaxy Fontan counterpart [13-17]. These limitations are summarized in a recent 72 meta-analysis that identified 21 studies, but the median number of patients per study was only 24 with median follow-up of 4  $\frac{1}{2}$  years [18]. The meta-analysis found a significantly 73 74 higher early mortality (14%) with a 10-year survival of 74%. A notable finding was that 75 early mortality remains high even among the recent studies, whereas survival has been 76 improved in other anatomic subgroups undergoing Fontan operation [18].

77

There are few large single centre studies in which consistent techniques for the Fontan procedure have been used [17,19]. However, the role of the different techniques of Fontan modification in heterotaxy have never been studied in detail with respect to their

influence on long-term outcomes. This study aimed to analyze the impact of cardiac
structures and individualized operative approaches, including a low threshold to intervene
on PV stenosis in the setting of RAI, at the time of Fontan operation. To assess these
outcomes in context, the heterotaxy group were compared with two contemporaneous
cohorts, the 'ideal' Fontan (Tricuspid Atresia cohort, TA), and a higher risk Fontan group
(Hypoplastic Left Heart Syndrome cohort, HLHS) [20-22].

87

#### 88 Patients and Methods

89 The study protocol was approved by the Research Ethics Board, the Hospital for Sick Children, Toronto, Ontario, Canada (ID 1000071680). The cardiovascular surgery 90 91 database at the Hospital for Sick Children was reviewed for all patients with heterotaxy 92 syndrome, TA, and HLHS undergone a Fontan operation. Among the 551 patients who 93 underwent Fontan operation between January 1985 to September 2021: 82 with heterotaxy (15%), 150 with TA (27%), and 144 with HLHS (26%) were reviewed. 94 95 Heterotaxy diagnosed in preoperative imaging modalities, was including echocardiography, magnetic resonance imaging and computed tomography, and by 96 97 intraoperative findings.

Data collected included demographics, underlying anatomy, operative details, and long-term follow-up data. The analysis included the subset of patients with hetarotaxy, subdivided into those with RAI (n=45) and those with left atrial isomerism (LAI) (n=37). Reoperation was defined as all cardiac surgical interventions except for permanent pacemaker implantation, generator change, and heart transplantation (HTx). The term "the IVC" in the manuscript is defined as the IVC or hepatic veins (HVs) with interrupted

104 IVC draining into the atrium. ACJ was a morphologic feature of the cardiac apex pointing 105 toward the ipsilateral side of the IVC [23]. The IVC-ipsilateral pulmonary artery (PA) 106 Fontan indicates a Fontan route placed between the IVC and ipsilateral PA at the side of 107 the cardiac apex or a Fontan route running between the IVC draining into the mid-atrium 108 to the PA behind the ventricular mass, as opposed to the standard Fontan, in which a 109 Fontan route is placed in the opposite side of the cardiac apex between the IVC and 110 ipsilateral PA. The IVC-contralateral PA Fontan represents an extracardiac Fontan conduit 111 passing over the vertebra to run to the contralateral PA. Although it has been routine to 112 create a fenestration since early 2000's, the decision to create a fenestration in heterotaxy was individualized based on multiple factors, including physiology, anatomical limitations, 113 114and surgical judgement. A fenestration was typically not created in patients with 115 arteriovenous malformation (AVM) or who previously underwent Kawashima procedure. 116 Early death or reoperation are defined as death or surgical intervention within one-month 117 post-Fontan, while late death represents death later than one-month post-Fontan.

118

#### 119 **Data analysis**

120 Clinical characteristics at the index surgery were summarized using descriptive statistics. 121 Continuous variables were summarized using median, the first and third quartile, 122 categorical variables were summarized by frequencies. The freedom from death or HTx 123 was characterized using the Kaplan-Meier survival method, and between-group 124 differences in HTx-free survival were evaluated using log rank tests. The length of stay 125 (LOS), reoperation and the incidence of moderate or greater systolic dysfunction and AV 126 valve regurgitation (AVVR) were characterized using Fine and Gray's subdistribution

method, in which death or HTx was considered a competing risk, in terms of cumulative
 incidence function (CIF). Between-group differences in CIF were evaluated using Gray's
 tests.

130 The associations of heterotaxy with the HTx-free survival was assessed and guantified using a Cox proportional hazard model in terms of hazard ratios (HRs). The 131 132 association of heterotaxy with the LOS, reoperation and the incidence of moderate or 133 greater systolic ventricular dysfunction and AVVR using the subdistribution regression 134 method was quantified in terms of subdistribution HRs. We conducted each analysis with 135 and without covariate adjustment. The covariates included the year of the Fontan, age and sex at the Fontan, the presence of fenestration, and other concomitant AV valve 136 137 repair. In all regression analyses, the year of the Fontan and age at the Fontan, were 138 modeled using natural cubic splines to account for their potential nonlinear associations 139 with the outcomes; hence, the corresponding results were shown graphically. The 140 corresponding 95% confidence interval (CI) and p-values was evaluated using Wald's 141 statistics. Finally, we conducted an exploratory analysis to assess clinical risk factors 142specified *a priori* on HTx-free survival using a Cox proportional hazard model. The risk 143 factors under consideration included ventricular morphology, laterality of the apex of the 144 heart, laterality of Fontan pathway, the IVC on the same side as the apex, repair of 145 pulmonary venous obstruction, AV valve repair and Fontan route on the same side as the 146 apex. Missing values were imputed using multivariable imputation with a chained 147 equation. The imputed results were pooled using Rubin's method. Statistical analyses 148 assumed a significance level of 5% and were conducted in R v4.0.3.

149

#### 150 **Results**

The median (Q1-Q3) follow-up was 11 (3.9-20), 12 (5.3-24), and 13 (4.3-18) years for heterotaxy, TA, and HLHS, respectively. Clinical characteristics of these cohorts are described in Table S1.

154

# 155 Anatomical Features and Fontan Techniques in Heterotaxy

156 Baseline characteristics, anatomical features, Fontan techniques in the RAI and LAI are 157 shown in Table1. Representative figures of Fontan pathway in each technique: standard 158 extracardiac, intra-atrial conduit, IVC-ipsilateral PA, and IVC-contralateral PA Fontan, are shown in Figure 1. Applied surgical approaches according to locations of the IVC to the 159 160 cardiac apex are summarized in Figure S1. Atrioventricular septal defect was present in 161 most patients (76%) and in similar rate between RAI and LAI. The dominant ventricle was 162 RV in 50% of RAI and in 70% of LAI. Dextrocardia was present in 29% of RAI and in 46% of LAI. ACJ was present in 22% of the whole cohort. 163

The IVC was interrupted in 84% of LAI and in 2% of RAI. All patients with interrupted IVC underwent Kawashima procedure. There was no difference in age at Fontan completion between the patients who previously underwent Kawashima procedure and the patients who did not (age in years at the Fontan completion with vs. without previous Kawashima, 4.7 [3.2-7.3] vs. 4.2 [3.1-6.8], years old, p=0.82). The IVC (or HVs in the setting of interrupted IVC) drained to the right-sided atrium in approximately 50%, to the left-sided atrium in 35%, and to the midline in 12%.

An extracardiac Fontan was the commonest technique, used in 66% of the cases (71% RAI and 59% LAI) with a polytetrafluoroethylene (PTFE) graft (GORE-TEX Stretch

173 Vascular Graft, GORE, Flagstaff, AZ) with the size ranging from 16 to 22mm. A Y-graft 174 was used in 5 cases (all LAI) who had unilateral or bilateral AVM to ensure IVC flow to both lungs. The second commonest Fontan type was a lateral tunnel, used in 18% of 175 176 cases, which were equally distributed in both RAI and LAI. An intra-atrial conduit Fontan 177 was used in seven cases (9%) (no difference in RAI vs. LAI). Of which two woven double 178 velour graft (20 and 24mm, respectively, Hemashield, GETINGE, Göteborg, Sweden) was 179 used and a PTFE graft (16 to 18 mm) was used in 5 patients in order to avoid pulmonary 180 venous compression typically in cases of midline IVC or ACJ (see Fig 1c). Three patients 181 in the very early cohort had an atrio-pulmonary connection.

In terms of laterality of the Fontan route, 37% of RAI and 41% of LAI patients had a left sided conduit. This was strongly correlated with the incidence of dextrocardia (37%) and with the IVC (or HVs in the case of interrupted IVC) draining into the left-sided atrium (35%). There were six (8%) and 12 patients (15%) undergone IVC-contralateral PA Fontan and IVC-ipsilateral PA Fontan, respectively.

187

#### **188 Concomitant Procedures**

Fenestration was performed in 65% of cases and was commoner in RAI (84%) than LAI (41%) (p<0.001). PV repair was performed in 18% of RAI patients and 0% of LAI (p<0.001) with zero recurrence of PV obstruction postoperatively. PA plasty and AV valve repair were performed for 18% and 15% of the patients, respectively, without significant difference between RAI and LAI.

194

### 195 Control Groups: TA and HLHS

196 Clinical characteristics of the comparison cohorts with TA or HLHS undergoing Fontan 197 are described, in Table S1. In comparison to patients with TA and HLHS, weight and age 198 at the Fontan for patients with heterotaxy were larger and older. Fenestration creation 199 was more common in the HLHS cohort than heterotaxy.

200

#### 201 Early outcomes

The competing risk analysis showed that hospital (4-week) mortality (95% CI) was 202 203 significantly higher in heterotaxy (9.8% [5.1-19%]) than TA (1.3% [0.3-5.3%], p<0.01) or 204 HLHS (2.8% [1.1-7.3%], p=0.02) patients, while there was no significant difference between RAI and LAI (11% [4.3-27%] vs. 8.9% [3.5-23%], p=0.72) (Figure 2.1). The 205 206 estimated proportion (95% CI) of patients discharged from hospitalization alive within 4 207 weeks was significantly lower in heterotaxy (79%, [71-89%]) than TA (91%, [86-95%], 208 p=0.008) or HLHS (90%, [86-95%], p=0.003); there was no significant difference between 209 RAI and LAI (78% [66-93%]; 80% [69-93%]; p=0.77) (Figure S2).

210 Moreover, the results of subdistribution regression analysis showed that heterotaxy was 211 significantly associated with a reduced likelihood of being discharged alive (thus more 212 likely to die during the index hospitalization) (Table 3) compared to TA or HLHS. It was 213 estimated that heterotaxy was associated with an approximate 40% reduction in the 214 likelihood of a live discharge compared to TA (HR [95% CI] = 0.64 [0.47, 0.89], p = 0.007) 215 or compared to HLHS (0.75 [0.54, 1.03], p = 0.08). It is also noteworthy that significant 216 improvement in terms of the incidence of live discharges year over year in all groups (RAI 217 and LAI, heterotaxy and TA, and heterotaxy and HLHS) (Figure 3) and that the covariate-218 adjusted effect of Fontan year on HTx-free survival was not statistically significant (Figure

S3). Modes of early death in heterotaxy are summarized in Figure S4. Notably, three out of 11 early deaths occurred in the IVC-ipsilateral PA group, of which two occurred during the index hospitalization due to failed Fontan circulation, and the other patient died at home nine days post-Fontan.

Early reoperation was required for six (7.3%) heterotaxy, two (1.3%) TA, and one (0.7%)

HLHS patient (Table S1, Figure 4). Among those with early reoperation, Fontan takedown

was required in two heterotaxy, one TA, and one HLHS patient during the index admission

with three in-hospital deaths except for one TA post-Fontan takedown.

227

#### 228 Late outcomes

There were in total 20 heterotaxy, 8 TA and 22 HLHS patients who subsequent died or 229 230 received HTx during the follow-up. The proportion of deceased or transplanted patients in each group is shown in Figure 2.2 and modes of late death or HTx are shown in Figure 231 S4. There was no significant difference in the 20-year HTx-free survival between RAI and 232 233 LAI populations. The HTx-free survival (95% CI) at 20 years after Fontan was significantly 234 better in TA (95%, [89-97%]) than that in heterotexy (72%, [59-82%], p<0.001) and not 235 significantly different between heterotaxy and HLHS (80%, [69-87%], p=0.11). The 236 findings remained consistent among hospital survivors, in which the 20-year HTx-free 237 survival remained significantly lower in heterotaxy (82% [67-90%]) than that in TA (96% 238 [90-98%], p<0.01) and not significantly different from that in HLHS (82% [71-89%], p=0.94). The multivariable Cox proportion hazard regression showed that the risk of death 239 240 or HTx was significantly higher in the heterotaxy than the TA patients (adjusted HR [95% 241 CI = 4.2 [1.5, 12], p = 0.007) and not significantly different from the HLHS patients

242 (adjusted HR [95% CI] = 1.2 [0.5, 2.7], p = 0.63) (Table S2).

243 There were in total 13 heterotaxy, 13 TA and 8 HLHS patients who received reoperations during the follow up. The estimated proportion (95% CI) of reoperation at 20 years after 244 245 Fontan in the heterotaxy group (18%, [11-29%]) was not significantly different from that 246 in TA (11%, [6.0-21%], p=0.07) but was significantly higher than that in HLHS (7.5% [3.7-247 16%], p=0.01) (Figure 4). There were no significant differences in the incidence of 248 reoperation between RAI and LAI. Moreover, late reoperation was required for seven 249 (9%), eleven (7%), and seven patients (5%) in heterotaxy, TA, and HLHS, respectively 250 (Table S1). One of two Fontan revisions in heterotaxy was attributed to PV obstruction caused by the intra-atrial Fontan conduit, for which mobilization of the conduit and repair 251 252 of the PV obstruction were performed. Another Fontan revision was thrombectomy from 253 the Fontan conduit. Retrieval of a fenestration closure device was needed in one patient.

254

#### 255 **Ventricular Dysfunction and AVVR in Heterotaxy**

256 The impact of moderate or greater systolic ventricular dysfunction and moderate or 257 greater AVVR among the hospital survivors in the heterotaxy group are shown in Figure 258 5. None of the LAI patient developed moderate or greater ventricular dysfunction, while 259 the estimated proportions of RAI patients who developed moderate or greater ventricular 260 dysfunction were 2% (0.3-15%), 6% (2-24%), 15% (6-39%) at 10-, 15-, and 20-years post-261 Fontan. The proportions of patients with moderate or greater AVVR were 17% (9-34%) at 10 and 15 years and 42% (27-65%) at 20 years in RAI, while those in LAI were 6% (2-262 263 25%) at 10 years and 16% (6-40%) at 15 and 20 years. There was no statistical 264 significance in the incidence of ventricular dysfunction (p=0.09) and AVVR (p=0.10)

between RAI and LAI.

266

267

#### 268 **Risk Analysis for HTx-free Survival**

The univariate analysis showed no anatomical and Fontan characteristics associated with HTx-free survival in heterotaxy (Table 2). The technique of routing the extracardiac conduit to the contralateral side of the cardiac mass (n=6) was associated with no early or late mortality and no pathway obstruction, although there was no statistical significance compared to other routing techniques. By contrast, there were 4 deaths out of 12 patients with IVC-ipsilateral PA Fontan over the period, showing HTx-free survival at 67% [34-87%] at 20 years.

276

### 277 Discussion

This series constitutes a large single-centre experience of Fontan operation for patients 278 279 with heterotaxy with median follow up of over 11 years. Despite concerns over the long-280 term outcomes for RAI, the study showed improved outcomes for RAI that are 281 comparable to those of LAI. This may have been achieved through the aggressive 282 treatment for PV stenosis at the time of Fontan operation and individualized Fontan 283 configurations, such as the intra-atrial conduit to avoid compression on PVs. The majority 284 of early mortality in the cohort occurred before 2000 and all three groups have universally 285 excellent survival in the current era. Compared with HLHS, the heterotaxy group had an 286 early hazard of death and HTx and but similar constant low late hazard, making equivalent 287 survival between heterotaxy and HLHS among the hospital survivors.

288

#### 289 Individualized Fontan Techniques

290 The study demonstrated no significant impact of the ventricular morphology and 291 positioning, presence of ACJ, laterality of the Fontan route, types of Fontan modifications, 292 and requirement of concomitant PV repair or AV valve repair at Fontan on HTx-free 293 survival in patients with heterotaxy. Although no single technique of Fontan had superior 294 outcomes, one important message was that, in the setting of ACJ, routing an extracardiac 295 conduit to the contralateral side to the apex showed no mortality and reoperation, while 296 routing the conduit to the ipsilateral side to the apex was associated with some mortalities. Previous reports of Fontan for patients with ACJ showed various strategies and mixed 297 298 results. A small study of seven heterotaxy patients favored ipsilateral conduit (in 77% of 299 the cohort) with excellent survival [10] whereas the other studies favored contralateral 300 conduit in 54% and 86% of the cohorts, respectively [12, 24]. These practice variations 301 may stem from the efforts to mitigate the risks of PV obstruction in the IVC-ipsilateral PA 302 Fontan and systemic venous obstruction in the IVC-contralateral PA Fontan [12,23,25,26]. 303 To address these drawbacks of the techniques, intra-atrial conduit and intra-extracardiac 304 Fontan techniques have gained renewed interest, even in more standard anatomy as they 305 allow for anterior positioning of the conduit away from the PVs and can be reliably 306 fenestrated [27-29].

307

#### 308 Heterotaxy vs TA and HLHS

309 One of the main objectives of this study is to compare outcomes of heterotaxy patients 310 to a contemporaneous cohort of ideal and high-risk Fontan categories – TA and HLHS.

311 We found that HTx-free survival and hospital mortality in TA were superior to those in 312 heterotaxy, while the reoperation rate was comparable between TA and heterotaxy groups. Despite having the higher hospital mortality and reoperation rate, heterotaxy had 313 314 comparable HTx-free survival to HLHS over 20 years. The era effect needs to be taken 315 into consideration as a potential factor to alleviate early mortality in heterotaxy. Despite 316 no statistical difference in the covariate-adjusted year effect on HTx-free survival over the 317 20 years (Figure S3). There has been no hospital death since 2000 in any subgroups. 318 Therefore, future study to analyze contemporary cohort may look different than the 319 outcomes shown in this study.

320

#### 321 Impact of Ventricular Dysfunction and AVVR

322 In univariate analysis, moderate or greater systolic dysfunction was revealed as a 323 significant risk factor for death or HTx in patients with heterotaxy. Moderate or greater 324 AVVR was not identified as the predictor for death or HTx in this study, which could partly 325 be explained by the shorter follow-up period. In the longer follow-up, more patients with 326 significant AVVR might have functional deterioration, as AVVR was identified as an 327 independent risk factor of the long-term outcomes in previous reports [30,31]. The 328 important facts in this study are well-maintained systolic function for the first 13 years after 329 Fontan and steady increase in the rate of significant AVVR over time particularly among 330 the patients with RAI. Since there is a significant negative impact of systolic dysfunction 331 on HTx-free survival and significant AVVR can lead to ventricular functional deterioration, 332 early intervention for AVVR in heterotaxy should be considered to prevent ventricular 333 dysfunction and poor outcomes.

334

#### 335 Study limitations

There are two major limitations of this study: its retrospective nature and a small number 336 337 of Fontan patients with heterotaxy, despite this being one of the largest single-centre series to date. Thus, regression analysis for short-term outcomes, including the era effect, 338 339 was not conducted. Future analysis might be beneficial in identifying potential risks to 340 early Fontan mortality and rather in describing if heterotaxy remains a high-risk group for 341 the early post-Fontan outcome considering the era effect. In the present study, eligibility 342 criteria for Fontan's candidacy were not considered and patients in the heterotaxy cohort 343 were pre-selected, excluding the ones who had not successfully undergone the Fontan 344 completion.

345

#### 346 Conclusions

Heterotaxy remains a high-risk group for Fontan completion, characterized by a high early 347 348 mortality compared to other Fontan substrates. The individualized Fontan routing strategy 349 effectively prevented systemic venous and PV obstruction. Routing the conduit to the 350 contralateral side of the ventricular mass is potentially beneficial to the patients with ACJ and related abnormalities. The potential higher risk of RAI can be mitigated by 351 352 concomitant correction of any PV anomaly at time of Fontan and use of fenestration. 353 Heterotaxy Fontan outcomes is equivalent to those of HLHS, and the late incidence of 354 reintervention is low. Ventricular dysfunction is associated with late death and HTx.

355

#### 356 Acknowledgement: None

357

#### 358 **Sources of Funding**: No funding

- 359
- 360 **Disclosure**: None
- 361
- 362 **References**:

Jacobs JP, Anderson RH, Weinberg PM, Walters HL 3rd, Tchervenkov CI, Del
 Duca D, Franklin RC, Aiello VD, Béland MJ, Colan SD, Gaynor JW, Krogmann ON,
 Kurosawa H, Maruszewski B, Stellin G, Elliott MJ. The nomenclature, definition and
 classification of cardiac structures in the setting of heterotaxy. Cardiol Young. 2007;17
 Suppl 2:1-28.

Lim HG, Bacha EA, Marx GR, Marshall A, Fynn-Thompson F, Mayer JE, Del
 Nido P, Pigula FA. Biventricular repair in patients with heterotaxy syndrome. J Thorac
 Cardiovasc Surg. 2009 Feb;137(2):371-379.e3.

Graham G, Dearani JA, Niaz T, Crow S, Cetta F, Stephens EH. Outcomes of
 Biventricular and Single Ventricle Heterotaxy Patients: A Single Center Five-Decade
 Experience. Ann Thorac Surg. 2023 May;115(5):1206-1211.

4. Nakhleh N, Francis R, Giese RA, Tian X, Li Y, Zariwala MA, Yagi H, et al. High prevalence of respiratory ciliary dysfunction in congenital heart disease patients with heterotaxy. Circulation 2012;125:2232-42.

Sutherland MJ, Ware SM. Disorders of left-right asymmetry: heterotaxy and
 situs inversus. Am J Med Genet C Semin Med Genet 2009;151C:307-17.

6. Driscoll DJ, Offord KP, Feldt RH, Schaff HV, Puga FJ, Danielson GK. Five- to fifteen-year follow-up after Fontan operation. Circulation 1992;85:469-96.

381 7. Gentles TL, Mayer JE Jr, Gauvreau K, Newburger JW, Lock JE, Kupferschmid

382 JP, et al. Fontan operation in five hundred consecutive patients: factors influencing early

and late outcome. J Thorac Cardiovasc Surg 1997;114:376-91.

8. Hashmi A, Abu-Sulaiman R, McCrindle BW, Smallhorn JF, Williams WG,

385 Freedom RM. Management and outcomes of right atrial isomerism: a 26-year

386 experience. J Am Coll Cardiol 1998;31:1120-6.

387 9. Gaynor JW, Collins MH, Rychik J, Gaughan JP, Spray TL. Long-term outcome

388 of infants with single ventricle and total anomalous pulmonary venous connection. J

<sup>389</sup> Thorac Cardiovasc Surg 1999;117:506-13.

Gilljam T, McCrindle BW, Smallhorn JF, Williams WG, Freedom RM. Outcomes
 of left atrial isomerism over a 28-year period at a single institution. J Am Coll Cardiol
 2000;36:908-16.

Culbertson CB, George BL, Day RW, Laks H, Williams RG. Factors influencing
 survival of patients with heterotaxy syndrome undergoing the Fontan procedure. J Am
 Coll Cardiol 1992;20:678-84.

Chen W, Lu Y, Ma L, Yang S, Xia Y, Zou M, et al. Conduit Route Selection for
 Total Cavopulmonary Connection in Patients With Apicocaval Juxtaposition. Semin
 Thorac Cardiovasc Surg 2019;31:104-109.

Jonas RA. Surgical management of the neonate with heterotaxy and long-term
 outcomes of heterotaxy. World J Pediatr Congenit Heart Surg 2011;2:264-74.

401 14. Azakie A, Merklinger SL, Williams WG, Van Arsdell GS, Coles JG, Adatia I.

Improving outcomes of the Fontan operation in children with atrial isomerism and
 heterotaxy syndromes. Ann Thorac Surg. 2001;72:1636-40.

Stamm C, Friehs I, Duebener LF, Zurakowski D, Mayer JE Jr, Jonas RA, et al.
Improving results of the modified Fontan operation in patients with heterotaxy syndrome.
Ann Thorac Surg 2002;74:1967-77.

d'Udekem Y, Xu MY, Galati JC, Lu S, Iyengar AJ, Konstantinov IE, et al. Predictors
of survival after single-ventricle palliation: the impact of right ventricular dominance. J Am
Coll Cardiol 2012 27;59:1178-85.

17. Stephens EH, Graham G, Dearani JA, Niaz T, Cetta F. Fontan Palliation in
Patients with Heterotaxy Syndrome: A Five Decade Experience. World J Pediatr Congenit
Heart Surg 2022;13:436-442.

Marathe SP, Cao JY, Celermajer D, Ayer J, Sholler GF, d'Udekem Y, et al.
Outcomes of the Fontan Operation for Patients With Heterotaxy: A Meta-Analysis of 848
Patients. Ann Thorac Surg 2020;110:307-315.

416 19. Marathe SP, Zannino D, Cao JY, du Plessis K, Marathe SS, Ayer J, et al.
417 Heterotaxy Is Not a Risk Factor for Adverse Long-Term Outcomes After Fontan
418 Completion. Ann Thorac Surg. 2020;110(2):646-653.

Iyengar AJ, Winlaw DS, Galati JC, Gentles TL, Weintraub RG, Justo RN, et al.
The Australia and New Zealand Fontan Registry: description and initial results from the
first population-based Fontan registry. Intern Med J 2014;44:148-55.

Iyengar AJ, Winlaw DS, Galati JC, Wheaton GR, Gentles TL, Grigg LE, et al. The
 extracardiac conduit Fontan procedure in Australia and New Zealand: hypoplastic left
 heart syndrome predicts worse early and late outcomes. Eur J Cardiothorac Surg

425 **2014** ;**46**:**465-73**.

Iyengar AJ, Winlaw DS, Galati JC, Celermajer DS, Wheaton GR, Gentles TL,
Grigg LE, Weintraub RG, Bullock A, Justo RN, d'Udekem Y. Trends in Fontan surgery and
risk factors for early adverse outcomes after Fontan surgery: the Australia and New
Zealand Fontan Registry experience. J Thorac Cardiovasc Surg. 2014 Aug;148(2):56675.

23. Sakurai T, Kado H, Nakano T, Hinokiyama K, Oda S, Sugiura J, et al. The impact
of extracardiac conduit-total cavopulmonary connection on apicocaval juxtaposition. Eur
J Cardiothorac Surg 2010;38:439-44.

Imai K, Hoashi T, Shimada M, Komori M, Nakata T, Kurosaki K, Ichikawa H. Longterm Outcomes of Extracardiac Total Cavopulmonary Connection for Apicocaval
Juxtaposition. Ann Thorac Surg. 2021 Oct;112(4):1326-1333.

Yoshida M, Menon PG, Chrysostomou C, Pekkan K, Wearden PD, Oshima Y, et
al. Total cavopulmonary connection in patients with apicocaval juxtaposition: optimal
conduit route using preoperative angiogram and flow simulation. Eur J Cardiothorac Surg
2013;44:e46-52.

441 26. Kawahira Y, Nishigaki K, Ueno T. Extracardiac Fontan procedure bridging the 442 vertebra for apico-caval juxtaposition. Ann Thorac Surg. 2006;82:350-2.

443 27. Michielon G, Gharagozloo F, Julsrud PR, Danielson GK, Puga FJ. Modified 444 Fontan operation in the presence of anomalies of systemic and pulmonary venous 445 connection. Circulation 1993;88:II141-8.

28. Zhu ZQ, Hong HF, Chen HW, Zhang HB, Lu ZH, et al. Intraatrial conduit Fontan
procedure: indications, operative techniques, and clinical outcomes. Ann Thorac Surg

448 **2015;99:156-61**.

449 29. Hirose K, Ikai A, Murata M, Ito H, Koshiyama H, Ishidou M, et al. Intra-450 Extracardiac Total Cavopulmonary Connection for Patients With Anatomical Complexity.

- 451 Ann Thorac Surg 2021;111:958-965.
- 452 30. Zou MH, Cao F, Ma L, Chen WD, Li WL, Li J, Chen XX. Outcomes of the Surgical
- 453 Management of Atrial Isomerism and Functional Single Ventricle: A Single-Centered
- 454 Cohort From China. Front Cardiovasc Med. 2021 Sep 22;8:664752.
- 455 31. Alongi AM, Kirklin JK, Deng L, Padilla L, Pavnica J, Romp RL, Mauchley DC,
- 456 Cleveland DC, Dabal RJ. Surgical Management of Heterotaxy Syndrome: Current
- 457 Challenges and Opportunities. World J Pediatr Congenit Heart Surg. 2020 Mar;11(2):166-
- 458 **176**.
- 459
- 460 **Tables**
- Table 1. Demographic and operative variables in RAI and LAI.

Variables	Heterotaxy		RAI		LAI		
	Ν		N		N		P-value
Sex	82		45		37		0.04
Male		48 (59%)		31 (69%)		17 (46%)	
Female		34 (41%)		14 (31%)		20 (54%)	
Anatomical features							
Atrioventricular septal defect	82	62 (76%)	45	34 (76%)	37	28 (76%)	1
Ventricular morphorogy	81		44		37		0.12
Right ventricle	01	48 (59%)		22 (50%)	0,	26 (70%)	0.12
L eft ventricle		23 (28%)		17 (39%)		6 (16%)	
Biventricle in single ventricle		20 (20 %)		11 (0070)		0 (1070)	
physiology		8 (10%)		4 (9%)		4 (11%)	
Indetermined		2 (2%)		1 (2%)		1 (3%)	
The position of the cardiac apex	82	2 (270)	45	1 (270)	37	1 (070)	0.29
dextrocardia	02	30 (37%)	+5	13 (20%)	57	17 (46%)	0.23
		30 (37 %) 40 (60%)		13 (23%) 20 (67%)		10 (51%)	
levocardia		49 (60%)	_	30 (67%)		19 (51%)	
mesocardia		3 (4%)		2 (4%)		1 (3%)	
Location of the IVC or HVs with interrupted IVC	82		45		37		0.01
R		42 (51%)		22 (49%)		20 (54%)	
L		29 (35%)		21 (47%)		8 (22%)	
mid-portion		10 (12%)		2 (4%)		8 (22%)	
R and L HVs drain separately		1 (1%)		0 (-)		1 (3%)	
HVs draining into the atrium				- ( )		()	
separately from the IVC	82	13 (16%)	45	11 (24%)	37	2 (5%)	
Apicocaval juxtaposition	82	18 (22%)	45	10 (22%)	37	8 (22%)	1.00
Fontan characteristics	00	40(04 70)	45		07	4.0 (0.4 0.7)	0.70
Age at Fontan (years)"	82	4.3(3.1 - 7.3)	45	4.3(3.1 - 7.5) 14.3(13.1 - 20.5)	37	4.6(3.1-6.7) 16.0(12.0, 20.0)	0.79
Laterality of Fontan route	80	15.1 (13.0 – 20.4)	43	14.3 (13.1 – 20.3)	37	10.0 (12.9 – 20.0)	0.41
D	00	40 (61%)	+3	27 (63%)	57	22 (50%)	0.02
N		49 (01%)		27 (03%)		22 (39%)	
L Type of Fontan procedure	82	31 (39%)	45	10 (37 %)	37	13 (41%)	0.31
Extracardiac	02	54 (66%)		32 (71%)	57	22 (59%)	0.01
		15 (18%)		7 (16%)		8 (22%)	
		7 (0%)		2 (70/)		0 (2270)	
		7 (9%)		3(7%)		4 (11%)	
Allo-pullionary connection		3 (4%)		3(1%)		0 (-)	
Others		3 (4%)		0(-)		3 (0%)	
IVC-contralatoral BA Fontan	80	6 (8%)	13	5 (12%)	37	1 (3%)	0.44
IVC inside the DA Fonton at the	00	0 (0 /8)	43	5 (1276)	57	1 (3 %)	0.44
cardiac apex side	80	12 (15%)	44	5 (11%)	36	7 (19%)	0.36
Type of Fontan conduit	61**		35		26		0.02
PTFE graft		44 (72%)		29 (83%)		15 (58%)	
Aortic homograft		8 (13%)		5 (14%)		3 (12%)	
Y-shaped PTFE graft		5 (7%)		0 ()		5 (19%)	
Dacron graft		4 (7%)		1(3%)		3(12%)	
Associated procedures at Fontan		50 (0751)					
Fontan with tenestration	82	53 (65%)	45	38 (84%)	37	15 (41%)	<0.001
PA plasty at Fontan	82	15 (18%)	45	11 (24%)	37	4 (11%)	0.15
Atrioventricular valve repair at Fontan	82	12 (15%)	45	6 (13%)	37	6 (16%)	0.76
Repair of pulmonary venous obstruction at Fontan	82	8 (10%)	45	8 (18%)	37	0 (—)	<0.01
Reoperation post-Fontan	82	13 (16%)	45	6 (13%)	37	7 (19%)	0.55

- 463 HVs, hepatic veins; IVC, inferior vena cava; L, left; PA, pulmonary artery; PTFE,
- 464 Polytetrafluoroethylene; R, right. \*Median with interquartile range, \*\*Removing 21 cases
- with lateral tunnel (n=15), atrio-pulmonary connection (n=3), and others (n=3).
- 466

Variable	HR [95% CI]	P-value
Ventricular morphorogy		0.46
Biventricle in single ventricle physiology vs. Left ventricle	0.0 [0.0, Inf]	
Right vs. Left ventricle	2.0 [0.6, 6.7]	
Laterality of the apex of the heart		0.98
Dextrocardia vs. Levocardia	0.9 [0.3, 2.5]	
Mesocardia vs. Levocardia	0.0 [0.0, Inf]	
Hepatic veins draining into the atrium separately from the IVC	0.7 [0.1, 5.9]	0.71
Apicocaval jaxtaposition	0.6 [0.2, 2.2]	0.41
Laterality of Fontan pathway (Left vs. Right)	0.8 [0.3, 2.3]	0.68
IVC-ipsilateral PA Fontan at the side of the cardiac apex	1.5 [0.5, 5.0]	0.47
IVC-contralateral PA and intra-atrial conduit Fontan	0.2 [0.02, 2.2]	0.19
Repair of pulmonary venous obstruction at the Fontan	0.5 [0.1, 4.0]	0.45
Atrialventricular valve repair at the Fontan	1.1 [0.3, 4.3]	0.84

- 468 IVC, inferior vena cava; PA, pulmonary artery.
- 469

467

470 Table S1. Clinical characteristics of patients at and post-Fontan in Heterotaxy vs. TA or

471 HLHS

Variables	Heterotaxy			TA			HLHS	
	Ν		N		P-value*	N		P-value**
Sex	82	İ İ	150		1	144		0.056
Male		48 (59%)		88 (59%)			103 (72%)	
Female		34 (42%)		62 (41%)			41 (29%)	
Age at Fontan (years)	82	4.3 (3.1 – 7.3)	150	3.1 (2.6 – 3.9)	<0.001	144	3.2 (2.5 – 3.8)	< 0.001
Body weight at Fontan (kg)	82	15.1 (13.0 - 20.4)	150	13.6 (12.0 - 15.4)	<0.001	144	13.5 (12.5 -	< 0.001
Fontan with fenestration	82	53 (65%)	150	102 (68%)	0.66	144	124 (86%)	< 0.001
Reoperation post-Fontan	82	13 (16%)	150	13 (9%)	0.13	144	8 (6%)	0.02
Early reoperation								
Fontan takedown		2 (2%)		1 (0.7%)			1 (0.7%)	
Fontan revision		2 (2%)		-			-	
Pulmonary artery plasty		-		1 (0.7%)			-	
Subaortic stenosis repair		1 (1%)		-			-	
Late reoperation								
Fontan takedown		-		1 (0.7%)			2 (1%)	
Fontan revision		2 (2%)		1 (0.7%)			3 (2%)	
Fontan conversion		-		6 (4%)			-	
Fenestration closure device retrieval		1 (1%)		-			-	
Atrioventricular valve repair		2 (2%)		1 (0.7%)			1 (0.7%)	
Atrioventricular valve replacement		1 (1%)		-			-	
Pulmonary artery plasty		-		1 (0.7%)			-	
Pericardial drainage		1 (1%)						
Arterio-venous fistula creation		1 (1%)		-			-	
Bentall		-		1 (0.7%)			1 (0.7%)	

\* Heterotaxy vs. TA, \*\*Heterotaxy vs. HLHS

#### Table S2. The regression results on transplant-free survival

	Unadjusted		Covariate-adjusted	
Variable	HR [95% CI]	P-value	HR [95% CI]	P-value
LAI vs. RAI	1.6 [0.6, 3.9]	0.32	1.9 [0.6, 6.0]	0.25
Year of Fontan			Figure 4a	0.33
Age at Fontan (years)			Figure S4a	0.05
Female vs. male			0.4 [0.1, 1.1]	0.08
Fenestration			2.1 [0.4, 10.4]	0.35
Concomitant AV valve repair			1.2 [0.2, 6.5]	0.8
Heterotaxy vs. TA	5.3 [2.2, 12.5]	<0.001	4.2 [1.5, 11.9]	0.007
Year of Fontan			Figure 4b	0.15
Age at Fontan (years)			Figure S4b	0.004
Female vs. male			0.8[0.4, 1.9]	0.68
Fenestration			1.8 [0.5, 6.1]	0.32
Concomitant AV valve repair			1.3 [0.3, 5.0]	0.75
Heterotaxy vs. HLHS	1.7 [0.9, 3.3]	0.09	1.2 [0.5, 2.7]	0.63
Year of Fontan			Figure 4c	0.18
Age at Fontan (years)			Figure S4c	0.004
Female vs. male			1.0 [0.5, 2.0]	1
Fenestration			1.0 [0.4, 2.5]	0.95
Concomitant AV valve repair			1.1 [0.4, 2.8]	0.92

AV valve, atrioventricular valve.

# 479

# 480 Table S3. The regression results on discharge alive

	Unadjusted		Covariate-adjusted	
Variable	Subdistrict HR [95% CI]	P-value	Subdistrict HR [95% CI]	P-value
LAI vs. RAI	0.9 [0.6, 1.5]	0.72	0.6 [0.3, 1.0]	0.07
Year of Fontan			Figure S5.1a	0.03
Age at Fontan (years)			Figure S5.2a	0.54
Female vs. male			2.2 [1.2, 3.8]	<0.01
Fenestration			0.5 [0.2, 1.0]	0.06
Concomitant AV valve repair			0.6 [0.3, 1.2]	0.15
Heterotaxy vs. TA	0.6 [0.5, 0.8]	0.001	0.6 [0.5, 0.9]	<0.01
Year of Fontan			Figure S5.1b	<0.001
Age at Fontan (years)			Figure S5.2b	0.5
Female vs. male			1.2 [0.9, 1.6]	0.21
Fenestration			0.8 [0.6, 1.2]	0.3
Concomitant AV valve repair			0.7[0.4, 1.4]	0.38
Heterotaxy vs. HLHS	0.6 [0.5, 0.8]	<0.001	0.7 [0.5, 1.0]	0.08
Year of Fontan			Figure S5.1c	<0.001
Age at Fontan (years)			Figure S5.2c	0.36
Female vs. male			1.1 [0.8, 1.5]	0.54
Fenestration			0.6 [0.4, 0.9]	<0.01
Concomitant AV valve repair			0.8 [0.6, 1.3]	0.39

481

482 AV valve, atrioventricular valve.

483

484

485 **Figures and Figure Legends** 



486

Figure 1. Fontan modifications. (a) right-sided extracardiac Fontan, (b) left-sided extracardiac Fontan, (c) intra-atrial conduit Fontan, (d) the IVC-ipsilateral PA Fontan, in which the arrow head indicates the conduit running behind the ventricular mass and on the same side as the cardiac apex, (e) the IVC-contralateral PA Fontan. IVC, inferior vena cava; PA, pulmonary artery.











(2.2c)



Figure 2. The proportion of deceased or transplanted patients after Fontan operation. The follow-up period was during hospitalization post-Fontan (2.1) and over the period post-

Fontan (2.2). (a) RAI vs. LAI, (b) Heterotaxy vs. TA, and (c) Heterotaxy vs. HLHS.

498



500 Figure 3. Regression-adjusted year effect for discharge alive. In the combined cohorts of

501 RAI and LAI (a), Heterotaxy and TA (b), and Heterotaxy and HLHS (c).

502

499



Figure 4. Reoperation rate over time following Fontan operation. (a) RAI vs. LAI, (b)
heterotaxy vs. TA, and (c) heterotaxy vs. HLHS.



507

Figure 5. Development of systolic dysfunction and atrioventricular valve regurgitation (AVVR) in heterotaxy patients who survived to hospital discharge post-Fontan. (a) moderate or greater systolic dysfunction, (b) moderate or greater AVVR. The univariate analysis on death or transplant by development of moderate or greater ventricular dysfunction and AVVR after discharge are described in each figure. AVVR, atrioventricular valve regurgitation; CI, confidence interval; HR, hazard ratio.



515

Figure S1. Surgical approaches using IVC-contralateral PA Fontan, IVC-ipsilateral PA
Fontan, and intra-atrial conduit Fontan. \*One of the patients with LIVC-L.apex relation is
unknown which Fontan modification was used. HV, hepatic vein; IVC, inferior vena cava;
L, left; PA, pulmonary artery; R; right.



522 Figure S2. Discharge alive within a month post-Fontan. (a) RAI vs. LAI, (b) heterotaxy vs.

# 523 TA, and (c) heterotaxy vs. HLHS.

524



526 Figure S3. Regression-adjusted year effect for transplant-free survival. In the combined

527 cohorts of RAI and LAI (a), Heterotaxy and TA (b), and Heterotaxy and HLHS (c).

528



530 Figure S4. Mode of death or heart transplant post-Fontan in the heterotaxy cohort. Al,

531 aortic insufficiency; AVM, arteriovenous malformation; AVVR, atrioventricular valve

regurgitation; PE, pulmonary thromboembolism; PLE, protein losing enteropathy.

533



535 Figure S5. Regression-adjusted age effect for transplant-free survival. In the combined

536 cohorts of RAI and LAI (a), Heterotaxy and TA (b), and Heterotaxy and HLHS (c).

537



538

539 Figure S6. Regression-adjusted age effect for discharge alive. In the combined cohorts 540 of RAI and LAI (a), Heterotaxy and TA (b), and Heterotaxy and HLHS (c).